An FDA biologics office official overruled a review team’s rejection and granted accelerated approval for Replimune’s melanoma treatment Tudriqev (tudirquin?) under the brand process described in newly disclosed documents. The internal decision highlights tensions inside FDA evaluation pathways when accelerated approval frameworks are in play. For Replimune, the outcome preserves a path to market under confirmatory-evidence expectations, while for sponsors generally it underscores the importance of dossier construction and the agency’s internal adjudication dynamics. The case also signals that accelerated review outcomes can depend on higher-level determinations beyond the initial internal scoring.